Kidswell Bio Corporation (4584.T)
- Previous Close
142.00 - Open
143.00 - Bid 141.00 x --
- Ask 142.00 x --
- Day's Range
138.00 - 143.00 - 52 Week Range
119.00 - 269.00 - Volume
121,900 - Avg. Volume
418,888 - Market Cap (intraday)
5.457B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-36.39 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease. In addition, its products also include GCT-101 for alveolar cleft; GCT-102 for congenital isolated hypoganglionosis; and other pipeline products for ophthalmologic diseases, cerebral palsy, peripheral nerve palsy, fracture, and spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
www.kidswellbio.comRelated News
Performance Overview: 4584.T
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4584.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4584.T
Valuation Measures
Market Cap
5.46B
Enterprise Value
5.54B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.09
Price/Book (mrq)
3.78
Enterprise Value/Revenue
2.12
Enterprise Value/EBITDA
-4.75
Financial Highlights
Profitability and Income Statement
Profit Margin
-16.09%
Return on Assets (ttm)
--
Return on Equity (ttm)
-17.95%
Revenue (ttm)
1.88B
Net Income Avi to Common (ttm)
-301.95M
Diluted EPS (ttm)
-36.39
Balance Sheet and Cash Flow
Total Cash (mrq)
624.51M
Total Debt/Equity (mrq)
240.62%
Levered Free Cash Flow (ttm)
--
Research Analysis: 4584.T
Company Insights: 4584.T
4584.T does not have Company Insights